Thermo Fisherpalns for the expansion of new dry powder media manufacturing facility.The facility is expanded to support the production of raw materials used for the manufacturing of new vaccines and biologic therapies.
The new expanision adds 45,000 square feet of Animal Origin Free (AOF) manufacturing space.
The new exapsnion is a part of US$650 million multi year investment project to support worldwide supply of media. Moreover, it advances the existing site capabilities to manufacture materials and technology required for the creation of commercial production of new vaccines and biologics including COVID-19 vaccines.
This expanion will address the urgernt supply of raw materials, by providing production redundancy and shorten product manufacturing lead times for customers.The new facility is expected to double the total bioprocess manufacturing capacity by the end of 2023.
The expansion creates more than 100 new jobs for staff across operations, manufacturing, R&D, operations, HR, engineering, and maintenance.